ABBVIE INC (ABBV)

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. The company offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. The company offers NX-13, a first-in-class, oral NLRX1 agonist, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383, a first-in-class anti-TREM1 antibody, for the treatment of inflammatory bowel disease.

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS 60064

P: 18479327900

CEO: Richard A. Gonzalez

Employees: 50000

Website: https://www.abbvie.com/